Allergan Board Selects Three New Members.

IRVINE, Calif.--(BW HealthWire)--Nov. 17, 1998--Allergan, Inc. (NYSE: AGN) announced the election of three new members to its Board of Directors: Michael R. Gallagher, Karen R. Osar, and Ronald M. Cresswell, Ph.D., effective today. These appointments increase the number of Allergan's directors to twelve.

Commenting on the appointments, Herbert W. Boyer, Ph.D., Chairman of the Board stated, "The addition of these three proven business leaders further strengthens our board and extends its breadth of experience in scientific research, consumer product marketing and international finance. Each of these individuals brings a different set of competencies to the board which complement those of our existing members. This will enhance the expertise and effectiveness of the board as a whole and ensure that, at this time of increased market growth for Allergan's product lines and of continued successes in research and development, strategic options for continued enhancement of shareholders' value are fully explored, developed and pursued."

Michael R. Gallagher, CEO of Playtex Products Inc., since 1995, brings invaluable broad-based personal care and consumer products experience to Allergan's board. Prior to Playtex, Mr. Gallagher was Chief Executive Officer for Reckitt & Colman North America, a $4 billion consumer products company based in London. Mr. Gallagher earned his reputation as he rose through the ranks of a variety of senior management positions over an eleven-year period for Sterling Drug, Inc. and Eastman Kodak, including CEO of L&F Products. He has also held senior positions at The Clorox Company and Procter & Gamble, where he began his career. He received both a bachelor's degree and an M.B.A. from the University of California at Berkeley.

Karen R. Osar currently serves as Tenneco Inc's Vice President and Treasurer and has a wide range of financial management experience. Tenneco is an $8 billion packaging and auto parts manufacturer with operations worldwide. Ms. Osar's expertise includes capital markets, foreign currency, mergers and acquisitions finance, IPOs, and structured finance. Previously, Ms. Osar served at J.P. Morgan for eighteen years in various positions of increased responsibility. She advanced through a number of international and corporate finance assignments and last served as a Managing Director in the Financial Institutions Group. Ms. Osar also worked at Banco do Brasil in New York after graduating from Smith College in Massachusetts. She earned her M.B.A. at Columbia University in New York.

Ronald M. Cresswell, Ph.D., world-renowned scientific leader and Chief Scientific Officer for Warner-Lambert Company, joins the Board with more than thirty years of international pharmaceutical company management experience, and an outstanding record of achievement in research and development. Dr. Cresswell, is a fellow of the Royal Society of Edinburgh, the Royal Society of Medicine, and the Royal Society of Arts and Commerce. He also serves on the board of Nycomed Amersham, plc. After receiving his bachelor of science and Ph.D. degrees in Applied Chemistry at the University of Glasgow, in Scotland, Dr. Cresswell completed post-doctoral work at Sloan Kettering Hospital in New York. He then became a senior biochemist at Burroughs Wellcome Company where he eventually was responsible for the company's worldwide R&D efforts. Subsequently, Dr. Cresswell joined Laporte Industries, Ltd. in London, where he served as Chief Operating Officer until joining Parke-Davis in 1988 as President of Parke-Davis Pharmaceutical Research, a division of Warner-Lambert Company.

David Pyott, President and CEO of Allergan commented, "I am truly delighted to have Karen Osar, Ronald Cresswell and Michael Gallagher join our board at this dynamic point in Allergan's history. After working through many necessary management and organizational changes this year, the addition of these new members to our board is yet another sign of our heightened commitment to act at every level in the company. These three accomplished individuals, along with our current board members, provide us with a board of experienced, proven business leaders who can offer sound operating and strategic advice to our top-notch management team as we seek to build upon our achievements as a global eye care and specialty pharmaceutical leader. I join the board, our shareholders, employees and customers in welcoming them to our prosperous, growing company."

Allergan, Inc. headquartered in Irvine, California, is a technology-driven, global health care company, providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets that deliver value to our customers, satisfy unmet medical needs and improve patients' lives.